大剂量地塞米松联合重组人血小板生成素对比单用大剂量地塞米松一线治疗新诊断成人原发免疫性血小板减少症:一项前瞻性、多中心、随机试验
这项前瞻性、多中心、随机对照试验纳入新诊断成人原发免疫性血小板减少症患者,比较地塞米松联合重组人血小板生成素与单用地塞米松的疗效与安全性,联合组初始反应率和完全反应率更高,6个月反应率及持续完全缓解率亦更高。
要点
- 联合组初始反应率89.0%高于单药组66.7%,P<.001。
- 联合组完全反应率75.0%高于单药组42.7%,P<.001。
- 6个月反应率联合组51.0%高于单药组36.5%,P=.02。
核心结论
- 大剂量地塞米松联合重组人血小板生成素显著提高新诊断成人原发免疫性血小板减少症患者的初始反应,并获得较好的持续缓解,作者认为可进一步验证其作为一线治疗。
研究设计与样本
- 前瞻性、多中心、随机、对照临床试验,全分析集纳入联合组100例、单药组96例新诊断成人原发免疫性血小板减少症患者。
- 入组患者随机接受地塞米松联合重组人血小板生成素或地塞米松单药治疗,两组若第10天未达反应则重复一个4天疗程的地塞米松。
- 试验注册号:clinicaltrials.gov identifier: NCT01734044。
主要发现
- 联合组初始反应率89.0% vs 单药组66.7%(P<.001)。
- 联合组完全反应率75.0% vs 单药组42.7%(P<.001)。
- 6个月反应率联合组51.0% vs 单药组36.5%(P=.02);持续完全缓解率联合组46.0% vs 单药组32.3%(P=.043)。
- Kaplan-Meier分析显示,随访期间联合组总体缓解持续时间长于单药组(P=.04)。
- 研究药物总体耐受良好。
临床怎么用
- 作者认为,大剂量地塞米松联合重组人血小板生成素可进一步验证作为原发免疫性血小板减少症的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a prospective, multicenter, randomized, controlled clinical trial to compare the efficacy and safety of high-dose dexamethasone (HD-DXM) plus recombinant human thrombopoietin (rhTPO), vs HD-DXM alone in newly diagnosed adult immune thrombocytopenia (ITP) patients. Enrolled patients were randomly assigned to receive DXM plus rhTPO or DXM monotherapy. Another 4-day course of DXM was repeated if response was not achieved by day 10 in both arms. One hundred patients in the HD-DXM plus rhTPO arm and 96 patients in the HD-DXM monotherapy arm were included in the full analysis set. So, HD-DXM plus rhTPO resulted in a higher incidence of initial response (89.0% vs 66.7%, P < .001) and complete response (CR, 75.0% vs 42.7%, P < .001) compared with HD-DXM monotherapy. Response rate at 6 months was also higher in the HD-DXM plus rhTPO arm than that in the HD-DXM monotherapy arm (51.0% vs 36.5%, P = .02; sustained CR: 46.0% vs 32.3%, P = .043). Throughout the follow-up period, the overall duration of response was greater in the HD-DXM plus rhTPO arm compared to the HD-DXM monotherapy arm (P = .04), as estimated by the Kaplan-Meier analysis. The study drugs were generally well tolerated. In conclusion, the combination of HD-DXM with rhTPO significantly improved the initial response and yielded favorable SR in newly diagnosed ITP patients, thus could be further validated as a frontline treatment for ITP. This study is registered as clinicaltrials.gov identifier: NCT01734044.
引用
- Yu Y, Wang M, Hou Y, et al. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial. Am J Hematol. 2020. PMID: 32871029. doi:10.1002/ajh.25989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。